All Oncology News

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

An NDA for lirafugratinib in pretreated, FGFR2-altered cholangiocarcinoma was accepted for FDA review and assigned a PDUFA date of September 27, 2026.

6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

We recap the top regulatory decisions of March in GI malignancies.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

Enolen was safe and feasible for the treatment of patients with early-stage prostate cancer.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Gotistobart improved response rates and overall survival vs docetaxel in pretreated squamous NSCLC in stage 1 of the PRESERVE-003 trial.

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Sac-TMT offered significant survival benefits vs docetaxel in pretreated EGFR-mutated NSCLC.

Neoadjuvant T-DXd followed by THP has received conditional approval in China for the treatment of patients with HER2-positive stage II/III breast cancer.

The EMA’s CHMP has recommended the approval of subcutaneous isatuximab via on-body injector for the treatment of multiple myeloma.

Subcutaneous daratumumab was approved in Europe for patient or caregiver administration in multiple myeloma.

The PI3Kα inhibitor risovalisib has been approved in Japan for PIK3CA-mutated ovarian clear cell carcinoma after progression on chemotherapy.

Theresa Guise, MD, and Stephanie S. Watowich, PhD, of The University of Texas MD Anderson Cancer Center, have been elected fellows of the American Association for the Advancement of Science.

Wendy Stock, MD, details key recommendations from the 2026 ASH guidelines for adolescent/young adult acute lymphoblastic leukemia management.

Zongertinib showed strong systemic and intracranial responses in HER2-mutant NSCLC with a manageable safety profile in Beamion LUNG-1.

Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC.

The ETOP ADEPPT trial met its primary end point with a 31% 12-week ORR with adagrasib in patients at least 70 years old with an ECOG PS of 0 or 1.

Real-world treatment with relugolix maintained QOL outcomes and had a manageable safety profile in patients with advanced prostate cancer.

Biomarker testing has added another layer to surgical planning in early-stage NSCLC, necessitating tighter multidisciplinary coordination.

Nodal clearance and pleural effusion after osimertinib induction were also identified as predictors of benefit with LCT in EGFR-mutated NSCLC.

Robert A. Winn, MD, has been named the next cancer center director for Fox Chase Cancer Center.

Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.

Jeffrey Zhong, MD, and Akshit Chitkara, MD, discuss 2 retrospective studies presented during the OncLive National Fellows Forum: Genitourinary Cancer.

Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC.